Truist Securities maintains Buy on Nurix, raises target to $34

0 min read | Published on 10 Jul 2026, 04:12 PM |Updated on 11 Jul 2026, 01:24 AM

Reviewed by

Radhika SScanX News Team

Key Highlights

Truist Securities analyst Gregory Renza maintained a Buy rating on Nurix Therapeutics and raised the stock's price target to $34 from $32.

*this image is generated using AI for illustrative purposes only.

Truist Securities analyst Gregory Renza has maintained a Buy rating on Nurix Therapeutics and increased the stock's price target to $34. The revision marks an increase from the previous target of $32.

Rating and Target Details

The updated guidance comes as the analyst reaffirms confidence in the company's prospects. The new price target of $34 represents a specific valuation outlook for the NASDAQ-listed shares.

Metric	Value
Rating	Buy
Previous Price Target	$32
New Price Target	$34

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific catalysts might drive Nurix Therapeutics' stock toward the new $34 price target?

How does the revised price target reflect the current market sentiment for biotech stocks?

What upcoming clinical trial results could further influence analyst ratings for Nurix?

RBC Capital raises Nurix Therapeutics price target to $33

0 min read | Published on 10 Jul 2026, 10:10 PM |Updated on 10 Jul 2026, 10:22 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

RBC Capital analyst Brian Abrahams maintained an Outperform rating on Nurix Therapeutics and increased the price target to $33 from $30, signaling confidence in the biotech firm's growth trajectory and potential market performance.

*this image is generated using AI for illustrative purposes only.

RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Nurix Therapeutics and raised the price target to $33 from $30. This adjustment reflects increased confidence in the company's stock performance and future growth trajectory.

The revised price target of $33 represents a notable increase from the previous target of $30. This move underscores the analyst's bullish stance on Nurix Therapeutics' prospects within the biotechnology sector.

Nurix Therapeutics, listed on NASDAQ under the ticker NRIX, continues to garner positive attention from market analysts. The maintenance of the Outperform rating alongside the higher price target suggests sustained optimism about the company's operational progress and pipeline potential.

Investors are likely to interpret this update as a reinforcement of the stock's investment appeal. The raised target may positively influence market sentiment and trading activity in the near term.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific operational milestones or pipeline advancements are likely driving the increased confidence in Nurix Therapeutics?

How might this price target adjustment influence other analysts' ratings and overall market sentiment toward NRIX?

What are the potential risks or challenges Nurix Therapeutics could face that could impact its ability to meet the new $33 price target?